Atreca has raised $ 125 m to step up research and development around the fresh approaches to cancer discovery that is continuing to attract attention . The company has received $ 500 m through venture capital rounds in recent years , investors including GlaxoSmithKline and the Bill & Melinda Gates Foundation supporting its method of probing the B - cell responses to identify novel antibodies and the targets that interact with them . The latest series C funding was provided by an anonymous " large US - based healthcare - focused fund " that has bankrolled cancer 's rise . Existing backers Wellington Management and Cormorant Asset Management contributed , with several new investors also coming aboard .
Atreca has raised $125m to step up research and development around the fresh approach to drug discovery that is continuing to attract attention. The company has received $91m through venture capital rounds in recent years, investors including GlaxoSmithKline and the Bill & Melinda Gates Foundation supporting its method of probing the B-cell responses to identify novel antibodies and the targets that engage with them. The latest series C round was led by an anonymous "large US-based healthcare-focused fund" that has bankrolled Atreca's rise. Existing backers Wellington Management and Cormorant Asset Management contributed, with several new investors also coming aboard.